Earnings ·
Faeth Therapeutics reports $16M net loss, raises cash to $186.4M via $200M PIPE financing
SNSESensei Biotherapeutics, Inc.
Faeth Therapeutics reported second quarter 2026 financial results and operational updates following its merger with Sensei Biotherapeutics and a concurrent $200 million PIPE financing. Cash, cash equivalents, and marketable securities increased to $186.4 million from $21.2 million at year-end 2025. Research and development expenses rose to $9.2 million from $2.5 million in the prior-year quarter, while general and administrative expenses reached $9.2 million compared to $2.7 million. The company reported a net loss of $16.0 million, or $2.84 per share, against a net loss of $4.9 million, or $3.91 per share, in the same period last year. Operational highlights include the first patient dosed in the Phase 1b/2 PIK-101 trial for HR+ breast cancer and expectations for topline data from the Phase 2 PIK-201 endometrial cancer trial by year-end. Faeth Therapeutics is a clinical-stage biotechnology company developing oncology treatments targeting the PI3K/AKT/mTOR pathway.